Peter LouwagieHead BD&L Partnering Immunology at Novartis
Peter Louwagie is the BD&L Partnering Immunology Head since 1 December 2022. Prior to this, Peter was the Global Head Business Development and Licensing Neuroscience. He was responsible for external innovation opportunities in Neuroscience's focus areas of movement disorders, neurodegenerative diseases, and neuropsychiatry. During this tenure, he led and negotiated the strategic collaboration with UCB for Parkinson’s Disease, and actively contributed on the Cadent acquisition and Voyager transaction.
Prior to this, he was a Senior Director Group M&A and led the team as a deputy head. He joined Novartis Group M&A in 2016 and led Novartis’ acquisitions of AAA, Endocyte, AveXis, Aspen Japan and The Medicines Company. Peter joined Novartis in 2011 in Business Development & Licensing for the Pharma Division. Before joining Novartis, Peter worked in the M&A department of UCB in Belgium.
Peter is a commercial engineer by training with specialization in Accounting and Tax earned at the Catholic University of Leuven (Belgium) and was a Certified Public Auditor in Belgium.
Peter Louwagie's Network
Novartis in neuroscience – translating strategy into science and partnering, 14:30View Session